BACKGROUND: We developed non-invasive, cell-based screening assays to rapidly and biologically assess factors that modulate prostate cancer growth and affect androgen receptor (AR) activity. METHODS: LNCaP cells, which stably express enhanced green fluorescent protein (EGFP) either constitutively or upon AR activation, were treated with a variety of agents, and then monitored by fluorescence and MTS assays for dose-dependent changes in cell number and AR activity. RESULTS: The assays were validated for rapid, fluorescence-based, quantitative measurement for the presence of growth and AR modulators. Using these assays, we found that osteoblast conditioned media (CM) enhanced prostate cancer cell growth, but not AR activity. After priming with androgen (<1 nM R1881), forskolin or the pesticide dichlorvos enhanced AR activation, whereas interleukin-6 (IL-6) inhibited it. CONCLUSION: These non-destructive, cell-based assays enable rapid systematic monitoring of the effects of drugs or complex mixtures on prostate cancer cell growth and/or AR activity.
BACKGROUND: We developed non-invasive, cell-based screening assays to rapidly and biologically assess factors that modulate prostate cancer growth and affect androgen receptor (AR) activity. METHODS: LNCaP cells, which stably express enhanced green fluorescent protein (EGFP) either constitutively or upon AR activation, were treated with a variety of agents, and then monitored by fluorescence and MTS assays for dose-dependent changes in cell number and AR activity. RESULTS: The assays were validated for rapid, fluorescence-based, quantitative measurement for the presence of growth and AR modulators. Using these assays, we found that osteoblast conditioned media (CM) enhanced prostate cancer cell growth, but not AR activity. After priming with androgen (<1 nM R1881), forskolin or the pesticide dichlorvos enhanced AR activation, whereas interleukin-6 (IL-6) inhibited it. CONCLUSION: These non-destructive, cell-based assays enable rapid systematic monitoring of the effects of drugs or complex mixtures on prostate cancer cell growth and/or AR activity.
Authors: Nathan A Lack; Peter Axerio-Cilies; Peyman Tavassoli; Frank Q Han; Ka Hong Chan; Clementine Feau; Eric LeBlanc; Emma Tomlinson Guns; R Kiplin Guy; Paul S Rennie; Artem Cherkasov Journal: J Med Chem Date: 2011-11-18 Impact factor: 7.446
Authors: Nada Lallous; Eric Leblanc; Ravi S N Munuganti; Mohamed D H Hassona; Nader Al Nakouzi; Shannon Awrey; Helene Morin; Mani Roshan-Moniri; Kriti Singh; Sam Lawn; Takeshi Yamazaki; Hans H Adomat; Christophe Andre; Mads Daugaard; Robert N Young; Emma S Tomlinson Guns; Paul S Rennie; Artem Cherkasov Journal: Mol Cancer Ther Date: 2016-10-07 Impact factor: 6.261
Authors: Mariia Radaeva; Fuqiang Ban; Fan Zhang; Eric LeBlanc; Nada Lallous; Paul S Rennie; Martin E Gleave; Artem Cherkasov Journal: Int J Mol Sci Date: 2021-03-02 Impact factor: 5.923